Cancer Personalized Medicine 2008

리서치사	Select Biosciences, Ltd.
발행일	2008년 07월	상품코드	70562
페이지 정보	166 pages
가격	US $ 4,140 ￦ 4,901,300 Hard Copy US $ 4,860 ￦ 5,753,700 PDF by E-mail (Site License)

한글목차
영문목차
관련자료

영문목차

Abstract

This is the latest most up-to-date Cancer Personalized Medicine Market Report from Select Biosciences. This report presents an up-to-date and thorough analysis of the Cancer Personalized Medicine Marketplace based upon Select Biosciences continuing industry coverage. Personalized Medicine, especially as it relates to Cancer, is undergoing significant growth and this report focuses in on the science, market/commercialization, and diagnostic/therapeutics trends in this space.

The Cancer Personalized Medicine marketplace represents the paradigm for personalized medicine market evolution and Select Biosciences focuses in this report on the various commercialized cancer predictor tests, their current status, traction in the marketplace, quantitative market opportunities, and the factors that are driving as well as challenging the expansion of this space.

Emerging classes of cancer biomarkers such as microRNAs and epigenetics are also examined in this report as well as the pipeline of RNAi-therapeutics for cancer. These biomarkers and treatment methodologies are drivers of the growth of the cancer personalized medicine marketplace for the future and therefore Select Biosciences provides coverage of these areas in this report-together with market participants making an impact in these particular areas.

Personalized Medicine marketplace is part of Select Biosciences continuous industry tracking and as part of this coverage; this report presents comprehensively the cancer personalized medicine market landscape in terms of:

Cancer Diagnostic Tests on the marketplace and in development that are developed as companion-diagnostics [coupled with a therapeutic regimen]
Landscape of In Vitro Diagnostic Multivariate Index Assays [IVDMIAs]-multigene predictors with prognostic/predictive value
Key Personalized Medicine Products in the Breast Cancer, Colon Cancer, etc. market spaces-together with the characteristics/features of These Products-HER2, oncotype DX™, MammaPrint®, UGT1A1, K-RAS, EGFR, etc.
Worldwide market survey completed recently-June 2008-of qualitative and quantitative market trends/metrics in this space. Report purchasers receive access to all the raw data from the market survey via access to secure server from Select Biosciences as well as all the annotated/analyzed data in the report. This highly valuable and recently collected dataset is based on an extensive market analysis performed by Select Biosciences Industry Analyst Team-all the raw data and analyses based on the data are presented in the report
Quantitative market forecast-for the year 2008 through 2011
Comprehensive profiles of the various market participants in this space
All report purchasers are entitled to 1 hour of free consultation with Select Biosciences Industry Analysts

Select Biosciences also includes in this report an overview of the drug metabolism and toxicity process, the role of specific cytochr ome P450 (CYP450) enzymes, and how these impact personalized medicine.

Furthermore, in this report are presented an overview of the FDA-regulatory process on In Vitro Diagnostic Multivariate Index Assays (IVDMIAs), and how this impacts the market acceptance of the various cancer personalized medicine tests either in development or out in the market.

Chapter I . Executive Overview of the Space

Molecular Diagnostics in Cancer: Breakout of the Market By Types of Tests and Their Value Proposition
Prognostic vs. Predictive Markers for Cancer
Personalized Medicine is Driving Cancer Treatment Decisions TODAY
Commercialization Metrics: Drugs vs. Diagnostics
The Lopsided Remuneration for Diagnostics: Personalized Medicine is Changing This Paradigm
Trajectory of Genomics-based Cancer Biomarker Tests, such as IVDMIAs, for Personalized Medicine and Drivers for Market Acceptance
Trajectory of Genomics-based Cancer Biomarker Tests, such as IVDMIAs, for Personalized Medicine: Drivers and Challenges
Quantitative Market Metrics: Market Sizes
The Future of Cancer Personalized Medicine

Chapter II . Emerging Cancer Biomarkers for Personalized Medicine: microRNA-based, Epigenetics-based

Potential Role of microRNAs and Epigenetics in Cancer Personalized Medicine-The Potential Market Opportunities
A microRNA Cancer Map
microRNAs that are Associated with Human Cancers
microRNAs that may Regulate Cancer-related Genes - I Particular microRNAs may regulate specific cancer genes & their effect on cell function
microRNAs that may Regulate Cancer-related Genes - II. Alteration of microRNA expression in human malignancies
Epigenetic Alterations in Cancer
Predicted Impact of microRNA Diagnostics on Various Disease Areas and Associated Timelines
Predicted Impact of microRNA Therapeutics on Various Disease Areas and Associated Timelines
Rosetta Genomics Ltd., A Pioneer in Developing and Commercializing microRNA-based Cancer Diagnostics
Selected Market Participants Developing Epigenetics-based Cancer Personalized Tests

Chapter III . RNAi Therapeutics Landscape for Cancer 32-37

Chapter IV. Market Analysis: Cancer Personalized Medicine

Why Cancer Personalized Medicine? Value Delivered by the Diagnostic and Associated Value by the Therapeutic
Cancer Personalized Medicine: Anticancer drugs that can be used together with a pharmacodiagnostic test
Economics of Cancer Personalized Medicine
Multigene Predictors of Clinical Outcome for Breast Cancer
Comparison of Cost of Tests Across the Market Landscape for Breast Cancer Testing
Personalized Medicine in Other Cancers-A Complete Analysis of the Entire Landscape
Personalized Warfarin Therapy: Another Paradigm for the Personalized Medicine Marketplace
Cancer Personalized Medicine Worldwide Market Survey Data